**Supplementary Figure 1**. Seroprevalence of anti-HEV among (a) at-flare cases compared to matched controls, (b) flare cases’ post-flare samples compared to matched controls, and (c) anti-HEV seroprevalence of longitudinal samples among participants who experienced an ALT flare in the HBRN.